Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma, treatment of, localized ablative therapies in. Acne vulgaris, zinc for, 589 590 Acneiform dermatoses, zinc for, 589 593 Acreodermatitis enteropathica, 589 Actinic prurigo, thalidomide for, 579 Acute generalized exanthematous pustulosis (AGEP), topical metronidazole for, 531 532 Acute zinc deficiency, 589 Adalimumab described, 560 for HS, 514 515 AGEP. See Acute generalized exanthematous pustulosis (AGEP). Alefacept, for HS, 515 Alopecia, androgenetic. See Androgenetic alopecia. Alopecia areata, in children, innovative therapeutics in, 625 626 Androgen(s), androgenetic alopecia and, 612 613 Androgenetic alopecia androgens and, 612 613 genetics and, 612 zinc for, 591 Angioma(s), in children, innovative therapeutics in, 619 621 Antibiotic(s), for recurrent furunculosis, 481 483 Antimalarial agents, for SCLE, 494 Aphthous stomatitis, thalidomide for, 577 578 Atopic dermatitis, in children, innovative therapeutics in, 621 624 B B-cell lymphoma, cutaneous, primary, rituximab for, Behçet disease thalidomide for, 578 TNF-a for, 566 Belimumab, for SLE, 497 Benign familial pemphigus, TNF-a for, 569 570 Bexarotene gel, for severe hand dermatitis, 459 Biologic drugs, for HS, 513 521 Dermatol Clin 28 (2010) 631 637 doi:10.1016/s0733-8635(10)00107-5 0733-8635/10/$ see front matter ª 2010 Elsevier Inc. All rights reserved. adalimumab, 514 515 alefacept, 515 described, 513 514 efalizumab, 515 etanercept, 515 517 evidence-based grading of, 513 infliximab, 516, 518 521 Botulinum toxin, for severe hand dermatitis, 459 Bullous pemphigoid rituximab for, 549 550 TNF-a for, 564 C Calcineurin inhibitors, topical, 535 545. See also Topical calcineurin inhibitors. Chloroquine, for DLE, 493 Cholestatic itch, 468 469 Chronic cutaneous ulcers, zinc for, 593 Chronic inflammatory dermatoses, dapsone for, dosage of, 605 CLASI. See Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI). Community-acquired MRSA diagnosis of, 481 furunculosis and, 480 485 molecular pathogenesis of, 480 risk factors for, 480 481 treatment of, 481 Contact dermatitis, topical calcineurin inhibitors for, 537 Corticosteroid(s) for SCLE, 494 for severe hand dermatitis, 458 459 Crohn disease, cutaneous, topical calcineurin inhibitors for, 537 538 Cryotherapy, for cutaneous T-cell lymphoma, 503 504 Cutaneous B-cell lymphoma, primary, rituximab for, Cutaneous Crohn disease, topical calcineurin inhibitors for, 537 538 Cutaneous lupus erythematosus rituximab for, 551 Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI), 489 Cutaneous T-cell lymphoma, 501 510 described, 501 derm.theclinics.com
632 Cutaneous (continued) incidence of, 501 treatment of dichotomies in positioning therapies in, 501 502 localized ablative therapies in, 502 506 cryotherapy, 503 504 excimer laser, 504, 505 imiquimod, 504, 506, 507 photodynamic therapy, 502, 503 surgery, 504 palliation-related, generalized therapy in, 506 remission-related, generalized therapy in, 508 stem cell transplantation in, 508 Cutaneous ulcers, chronic, zinc for, 593 Cyclophosphamide plus azathioprine, for SLE, 496 D Dandruff, zinc for, 591 Dapsone adverse events with, 606 608 characteristics of, 603 chemistry of, 599 600 clinical use of, 603 605 dermatologic reactions to, 607 described, 599 gastrointestinal/hepatic reactions to, 607 608 hematologic effects of, 606 hypersensitivity syndrome with, 608 in chronic inflammatory dermatoses, dosage of, 605 innovative uses for, 599 610 mechanism of action of, 600 603 monitoring guidelines, 604 605 nervous system effects of, 607 pharmacology of, 599 600 pitfalls of, 604 605 Dermatitis atopic, in children, innovative therapeutics in, 621 624 contact, diaper, zinc for, 591 592 hand, 453 465. See Hand dermatitis. perioral, periorificial, topical metronidazole for, 527 528 seborrheic topical metronidazole for, 527 zinc for, 591 zinc for, 591 592 Dermatomyositis rituximab for, 551 TNF-a for, 565 566 Dermatosis(es) acneiform, zinc for, 589 593 chronic inflammatory, dapsone for, dosage of, 605 inflammatory, chronic, dapsone for, dosage of, 605 perioral, subcorneal pustular, TNF-a for, 563 Diaper dermatitis, zinc for, 591 592 Discoid lupus erythematosus (DLE) described, 491 treatment of, 491 494. See also specific agents. DLE. See Discoid lupus erythematosus (DLE). Drug eruptions, fixed, topical metronidazole for, 531 E Eczema, zinc for, 591 Efalizumab for DLE, 493 494 for HS, 515 Environmental decontamination, for recurrent furunculosis, 484 Epidermal growth factor receptor inhibitor associated cutaneous toxicity, topical metronidazole for, 528 530 Epidermolysis bullosa acquisita, rituximab for, 549 Epratuzumab, for SLE, 497 Erythema annular centrifigum, TNF-a for, 569 Erythema multiforme, thalidomide for, 580 Etanercept described, 560 for HS, 515 517 Excimer laser, for cutaneous T-cell lymphoma, 504, 505 F Female pattern hair loss (FPHL) androgens and, 612 613 causes of, 611 613 clinical features of, 613 614 diagnosis of, 613 614 genetics and, 612 pathophysiology of, 613 treatment of, 614 spironolactone in, innovative use of, 611 618. See also Spironolactone, in FPHL management, innovative use of. Fixed drug eruptions, topical metronidazole for, 531 Folliculitis decalvans, zinc for, 590 FPHL. See Female pattern hair loss (FPHL). Furunculosis, 479 487 bacterial milieu in, 479 480 chronic colonization in, treatment of, 483 484 environmental decontamination in, 484 community acquired MRSA and, 480 485. See also Community-acquired MRSA, furunculosis and.
633 G diagnosis of, 481 molecular pathogenesis of, bacterial milieu in, 480 recurrent prevention of, vaccines in, 486 treatment of, 481 484 antibiotics in, 481 483 environmental decontamination in, 484 for colonization in chronic furunculosis, 483 484 phages in, 484 risk factors for, 480 481 treatment of, 481 Genetic(s), in androgenetic alopecia, 612 Genodermatoses, in children, innovative therapeutics in, 627 628 Graft-versus-host disease (GVHD) rituximab for, 551 552 thalidomide for, 579 580 TNF-a for, 566 567 Granuloma annulare, TNF-a for, 561 GVHD. See Graft-versus-host disease (GVHD). H Hailey-Hailey disease, TNF-a for, 569 570 Hair, conditions affecting, zinc for, 591 Hand dermatitis causes of, 454 classification of, 453 454 described, 453 epidemiology of, 454 quality-of-life effects of, 454 455 severe, 453 465 defined, 453 diagnosis of, 455 456 laboratory studies in, 457 458 occupation in, 456 457 patch testing in, 455 456 severity assessments in, 455 prevention of, 458 risk factors for, 457 treatment of, 458 450 corticosteroids in, 458 459 ionizing radiation in, 459 systemic therapy in, 459 460 topical agents in, 458 459 Hidradenitis suppurativa (HS), 511 524 described, 511 diagnosis of, 512 symptoms of, 511 512 TNF-a for, 570 treatment of biologic drugs in, 513 521. See also specific drugs and Biologic drugs, for HS. tradition therapies in, 512 513 zinc for, 590 Histiocytosis, Langerhans cell, thalidomide for, 580 HS. See Hidradenitis suppurativa (HS). Hydroxychloroquine, for DLE, 493 Hypersensitivity syndrome, dapsone and, 608 I Imiquimod, for cutaneous T-cell lymphoma, 504, 506, 507 Immune diseases, in children, innovative therapeutics in, 625 627 Immunoglobulin(s), intravenous for SLE, 496 497 Infectious diseases in children, innovative therapeutics in, 624 625 zinc for, 592 Inflammatory dermatoses, chronic, dapsone for, dosage of, 605 Infliximab described, 559 560 for HS, 516, 518 521 Intravenous immunoglobulin (IVIG) for SLE, 496 497 Ionizing radiation, for severe hand dermatitis, 459 Itch. See also Pruritus. cholestatic, 468 469 defined, 467 neuropathic, 471 473 IVIG. See Intravenous immunoglobulin (IVIG). J Jessner lymphocytic infiltrate, thalidomide for, 581 K Kaposi sarcoma, thalidomide for, 581 L Langerhans cell histiocytosis, thalidomide for, 580 Laser(s) excimer, for cutaneous T-cell lymphoma, 504 pulsed dye, for DLE, 494 Leflunomide, Leishmaniasis, old-world cutaneous, zinc for, 592 Lenalidomide, for DLE, 493 Lichen planus, thalidomide for, 580 581 Lichen sclerosus, topical calcineurin inhibitors for, 538 Local zinc deficiency, 593
634 Localized ablative therapies, for cutaneous T-cell lymphoma, 502 506. See also specific types and Cutaneous T-cell lymphoma, treatment of, localized ablative therapies in. Lupus erythematosus, 489 499. See also specific types, e.g., Systemic lupus erythematosus (SLE). classification of, 489 490 cutaneous presentation of, 489 rituximab for, 551 subacute, 494 495 described, 489 discoid, treatment of, 492 494. See also Discoid lupus erythematosus (DLE). systemic. See Systemic lupus erythematosus (SLE). thalidomide for, 578 579 Lymphoma(s) B-cell, cutaneous, primary, rituximab for, T-cell, cutaneous, 501 510. See also Cutaneous T-cell lymphoma. M Melasma, zinc for, 593 Methicillin-resistant Staphylococcus aureus (MRSA), community-acquired, furunculosis and, 480 485. See also Community-acquired MRSA, furunculosis and. Metronidazole, topical, 525 534 for rosacea, optimal use, 525 527 innovative uses of, 527 532 AGEP, 531 532 epidermal growth factor receptor inhibitor associated cutaneous toxicity, 528 530 fixed drug eruptions, 531 periorificial dermatitis, 527 528 seborrheic dermatitis, 527 smelly wounds, 530 531 mechanism of action of, 525 pharmacology of, 525 Moderate systemic zinc deficiency, 587 Morphea/scleroderma, topical calcineurin inhibitors for, 538 MRSA. See Methicillin-resistant Staphylococcus aureus (MRSA). Mucous membrane pemphigoid rituximab for, 550 TNF-a for, 564 Multicentric reticulohistiocytosis, TNF-a for, 568 569 Mycophenolate mofetil for SLE, 497 N Necrobiosis lipoidica diabeticorum thalidomide for, 582 TNF-a for, 561 562 Necrolytic acral erythema, zinc for, 592 593 Netherton syndrome, topical calcineurin inhibitors for, 538 Neuropathic itch, 471 473 Neuropathy(ies), peripheral, thalidomide and, 582 O Old-world cutaneous leishmaniasis, zinc for, 592 Oral lichen planus, topical calcineurin inhibitors for, 535 536 P Paraneoplastic pemphigus, rituximab for, 548 549 PASI. See Psoriasis Area Severity (PASI). Patch testing, in severe hand dermatitis, 455 456 PDL. See Pulsed dye laser (PDL). Pediatric dermatology, innovative therapeutics in, 619 629 alopecia areata, 625 626 angiomas, 619 621 atopic dermatitis, 621 624 genodermatoses, 627 628 immune diseases, 625 627 infectious diseases, 624 625 psoriasis, 624 scleroderma, 627 vitiligo, 626 627 Pemphigus foliaceus, rituximab for, 548 549 Pemphigus vulgaris, rituximab for, 548 549 Perioral dermatitis, topical calcineurin inhibitors for, 537 Periorificial dermatitis, topical metronidazole for, 527 528 Peripheral neuropathy, thalidomide and, 582 Phage(s), for recurrent furunculosis, 484 Photodynamic therapy, for cutaneous T-cell lymphoma, 502, 503 Pimecrolimus additional indications for, 539 for DLE, 492 for lichen sclerosus, 538 for Netherton syndrome, 538 for oral lichen planus, 535 for psoriasis, 537 for SLE, 496 for vitiligo, 536 Pityriasis rubra pilaris, TNF-a for, 567 568 Primary cutaneous B-cell lymphoma, rituximab for,
635 Prurigo nodularis, thalidomide for, 579 Pruritus, 467 478. See also Itch. classification of, 467 defined, 467 renal, 469 471 uremic, thalidomide for, 581 workup for, 467 468 Psoriasis in children, innovative therapeutics in, 624 topical calcineurin inhibitors for, 536 537 zinc for, 593 Psoriasis Area Severity (PASI), 489 Pulsed dye laser (PDL), for DLE, 494 Pyoderma gangrenosum thalidomide for, 581 582 TNF-a for, 562 563 Q Quality of life, severe hand dermatitis effects on, 454 455 Quinacrine, for DLE, 493 R Radiation, ionizing, for severe hand dermatitis, 459 Recalcitrant viral warts, zinc for, 592 Renal pruritus, 469 471 Reticulohistiocytosis, multicentric, TNF-a for, 568 569 Rituximab, 547 557 adverse effects of, incidence of, 547 548 described, 547 dosing regimen for, 547 for SLE, 497 indications for, 547 off-label uses of, 548 552 bullous pemphigoid, 549 550 cutaneous lupus erythematosus, 551 dermatomyositis, 551 epidermolysis bullosa acquisita, 549 GVHD, 551 552 mucous membrane pemphigoid, 550 paraneoplastic pemphigus, 548 549 pemphigus foliaceus, 548 549 pemphigus vulgaris, 548 549 primary cutaneous B-cell lymphoma, 550 vasculitis, 552 Romidepsin, for cutaneous T-cell lymphoma, 506 Rosacea topical metronidazole for, optimal use, 525 527 zinc for, 590 R-salbutamol, for DLE, 493 S SAPHO syndrome, TNF-a for, 568 Sarcoidosis thalidomide for, 579 TNF-a for, 560 561 Sarcoma(s), Kaposi, thalidomide for, 581 Scleroderma in children, innovative therapeutics in, 627 TNF-a for, 565 Scleromyxedema, thalidomide for, 582 Seborrheic dermatitis topical metronidazole for, 527 zinc for, 591 SLE. See Systemic lupus erythematosus (SLE). Smelly wounds, topical metronidazole for, 530 531 Spironolactone described, 614 in FPHL management, 611 618. See also Female pattern hair loss (FPHL). mechanism of action of, 615 response to, monitoring of, 615 616 Staphylococcus aureus, methicillin-resistant, community-acquired, furunculosis and, 480 485. See also Community-acquired MRSA, furunculosis and. Stem cell transplantation, for cutaneous T-cell lymphoma, 508 Stomatitis, aphthous, thalidomide for, 577 578 Subacute cutaneous lupus erythematosus (SCLE), 494 495 described, 494 treatment of, 494 495. See also specific agents. Subcorneal pustular dermatosis, TNF-a for, 563 Sunscreens, for SCLE, 494 Sweet syndrome, TNF-a for, 563 Systemic lupus erythematosus (SLE) described, 495 496 TNF-a for, 564 565 treatment of, 496 497. See also specific agents. T Tacrolimus, indications for, 492, 495, 535 539 DLE, 492 lichen sclerosus, 538 Netherton syndrome, 538 oral lichen planus, 535 psoriasis, 536 537 SCLE, 495 SLE, 496 vitiligo, 536 T-cell lymphoma, cutaneous, 501 510. See also Cutaneous T-cell lymphoma. Telgen effluvium, zinc for, 591 Teratogenicity, thalidomide and, 582
636 Thalidomide adverse effects of, 582 583 contraindications, 582 described, 577 off-label uses of, 577 586 actinic prurigo, 579 aphthous stomatitis, 577 578 Behçet disease, 578 erythema multiforme, 580 GVHD, 579 580 Jessner lymphocytic infiltrate, 581 Kaposi sarcoma, 581 Langerhans cell histiocytosis, 580 lichen planus, 580 581 lupus erythematosus, 578 579 necrobiosis lipoidica diabeticorum, 582 prurigo nodularis, 579 pyoderma gangrenosum, 581 582 sarcoidosis, 579 scleromyxedema, 582 uremic pruritus, 581 pharmacology of, 577 Thromboembolic events, thalidomide and, 582 583 TNF-a. See Tumor necrosis factor-a (TNF-a). Topical calcineurin inhibitors, 535 545. See also specific agents. innovative uses of contact dermatitis, 537 cutaneous Crohn disease, 537 538 cutaneous lupus erythematosus, 537 DLE, 492 lichen sclerosus, 537 morphea/scleroderma, 538 Netherton syndrome, 538 oral lichen planus, 535 536 perioral dermatitis, 537 psoriasis, 536 537 rosacea, 537 seborrheic dermatitis, 537 vitiligo, 536 Topical metronidazole, 525 534. See also Metronidazole, topical. Toxic epidermal necrolysis thalidomide for, contraindications, 582 TNF-a for, 569 Transplantation(s), stem cell, for cutaneous T-cell lymphoma, 508 Tumor necrosis factor-a (TNF-a), described, 559 Tumor necrosis factor-a (TNF-a) inhibitors, 559 575 adalimumab, 560 etanercept, 560 infliximab, 559 560 off-label uses of, 560 570 Behçet disease, 566 bullous pemphigoid, 564 dermatomyositis, 565 566 U erythema annular centrifigum, 569 granuloma annulare, 561 GVHD, 566 567 Hailey-Hailey disease, 569 570 hidradenitis suppurativa, 570 mucous membrane pemphigoid, 564 multicentric reticulohistiocytosis, 568 569 necrobiosis lipoidica diabeticorum, 561 562 pityriasis rubra pilaris, 567 568 pyoderma gangrenosum, 562 563 SAPHO syndrome, 568 sarcoidosis, 560 561 scleroderma, 565 SLE, 564 565 subcorneal pustular dermatosis, 563 Sweet syndrome, 563 toxic epidermal necrolysis, 569 vasculitis, 563 Ulcer(s), cutaneous, chronic, zinc for, 593 Uremic pruritus, thalidomide for, 581 V Vaccine(s), in recurrent furunculosis prevention, 486 Vaculitis-related conditions, zinc for, 591 Vasculitis rituximab for, 552 TNF-a for, 563 Viral warts, recalcitrant, zinc for, 592 Vitamin D for SLE, 496 plus calcium, for SCLE, 494 Vitiligo in children, innovative therapeutics in, 626 627 topical calcineurin inhibitors for, 536 W Wart(s), viral, recalcitrant, zinc for, 592 Wound(s), smelly, topical metronidazole for, 530 531 Z Zinc abnormalities associated with, dermatologic diseases attributed to, 587 589 described, 587 innovative uses of, 587 597 acne vulgaris, 589 590 acneiform dermatoses, 589 593 androgenetic alopecia, 591 chronic cutaneous ulcers, 593
637 conditions affecting hair, 591 dandruff, 591 dermatitis, 591 592 diaper dermatitis, 591 592 eczema, 591 folliculitis decalvans, 590 hidradenitis suppurativa, 590 indications for, 588 infectious diseases, 592 melasma, 593 necrolytic acral erythema, 592 593 old-world cutaneous leishmaniasis, 592 psoriasis, 593 recalcitrant viral warts, 592 rosacea, 590 seborrheic dermatitis, 591 study of discussion, 593 594 methods, 587 results, 587 593 telgen effluvium, 591 vasculitis conditions, 591